Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient.
A 35-year-old man with B lymphoblastic lymphoma was treated with bone marrow transplant and aggressive chemotherapy. He developed a Fusarium infection of the great toenail. Septicemic dissemination of a Fusarium sp. occurred 9 months later during a lymphoma relapse. The clinical course of the hyalohyphomycosis was then rapidly fatal despite institution of amphotericin B therapy.
Arrese
J E
JE
Department of Dermatopathology, University of Liège, Belgium.
Piérard-Franchimont
C
C
Piérard
G E
GE
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D017809:Fatal Outcome; D005533:Foot Dermatoses / Q000188:drug therapy / Q000473:pathology; D016469:Fungemia / Q000188:drug therapy / Q000382:microbiology; D005670:Fusarium / Q000302:isolation & purification; D006801:Humans; D016867:Immunocompromised Host; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000628:therapy; D008297:Male; D009181:Mycoses / Q000188:drug therapy / Q000473:pathology*; D009364:Neoplasm Recurrence, Local; D014009:Onychomycosis / Q000188:drug therapy / Q000473:pathology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000628:therapy
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D000666:Amphotericin B